Amiodarone-Induced Liver Toxicity
Authors: R. Michael Morse
Journal: Annals of Internal Medicine (1988)

Brief Reports15 November 1988Amiodarone-Induced Liver ToxicityR. Michael Morse, MD, Gregg A. Valenzuela, MD, Todd P. Greenwald, MD, Philip J. Eulie, MD, Robert C. Wesley, MD, Richard W. McCallum, MDR. Michael Morse, MDSearch for more papers by this author, Gregg A. Valenzuela, MDSearch for more papers by this author, Todd P. Greenwald, MDSearch for more papers by this author, Philip J. Eulie, MDSearch for more papers by this author, Robert C. Wesley, MDSearch for more papers by this author, Richard W. McCallum, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-10-838 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAmiodarone, a benzofuran derivative structurally related to thyroxine, has been used to treat heart disease for 25 years. It is an amphophilic compound that may induce secondary phospholipidosis. It can produce adverse events in up to 74% of patients at 1 year and 94% of patients at 3 years (1, 2) in a log linear relation to the total dose or duration of therapy. Reported side effects include corneal microdeposits, renal dysfunction, hypertriglyceridemia, nausea and vomiting, and photodermatitis; mental symptoms, such as fatigue, paresthesias, and sleep disturbances, have also been described. Toxic effects include increased atrioventricular or intraventricular conduction delay,...References1. Mason J. Toxicity of amiodarone. Circulation. 1985;72(Suppl 3):279A. Google Scholar2. Mason J. Amiodarone. N Engl J Med. 1987;316:455-66. CrossrefMedlineGoogle Scholar3. LubbeMercer WC. Amiodarone: its side effects, adverse reactions and dosage schedules. NZ Med J. 1982;95:502-4. MedlineGoogle Scholar4. PlomteuxHeusghemErnouldVandeghen GCHN. Long-term hepatic tolerance of amiodarone in the clinic. Eur J Pharmacol. 1969;8:369-76. CrossrefMedlineGoogle Scholar5. HarrisMcKennaRowlandHoltStoreyKrikler LWEDGD. Side effects of long-term amiodarone therapy. Circulation. 1983;67:45-51. CrossrefMedlineGoogle Scholar6. FogorosAndersonWinkleSwerdlowMason RKRCJ. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation. 1983;68:88-94. CrossrefMedlineGoogle Scholar7. LimTrewbyStoreyHole PPGD. Neuropathy and fatal hepatitis in a patient receiving amiodarone. Br Med J. 1984;288: 1638-9. CrossrefMedlineGoogle Scholar8. TordjmanKatzBursztynRosenthal KIMT. Amiodarone and the liver. Ann Intern Med. 1985;102:411-2. LinkGoogle Scholar9. AdamsHoltStoreyMorleyCallaghanCampbell PDGAJR. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation. 1985;72:1064-75. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: R. Michael Morse, MD; Gregg A. Valenzuela, MD; Todd P. Greenwald, MD; Philip J. Eulie, MD; Robert C. Wesley, MD; Richard W. McCallum, MDAffiliations: From the University of Virginia Health Sciences Center, Charlottesville, Virginia. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIodine accumulation of the liver in patients treated with amiodarone can be unmasked using material decomposition from multiphase spectral-detector CTA Novel Lipidomics-Based Approach to Evaluating the Risk of Clinical Hepatotoxicity Potential of Drugs in 3D Human MicrotissuesImmunohistochemical expression of autophagosome markers LC3 and p62 in preneoplastic liver foci in high fat diet-fed ratsAnalysis of computed tomography density of liver before and after amiodarone administrationScreening of herbal components for attenuating amiodarone-induced hepatotoxicity on gel-entrapped rat hepatocytesMechanisms of Hepatocellular Toxicity Associated with Dronedarone—A Comparison to AmiodaroneA Myriad of Pathways to NASHThe role of CYP3A4 in amiodarone-associated toxicity on HepG2 cellsHepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stagesAroclor 1254 induced cytotoxicity and mitochondrial dysfunction in isolated rat hepatocytesCausality assessment of liver injury after chronic oral amiodarone intakePharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodaroneHepatocellular Toxicity and Pharmacological Effect of Amiodarone and Amiodarone DerivativesPrevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunctionMechanisms of benzarone and benzbromarone-induced hepatic toxicityHépatotoxicité de l'amiodarone à propos de deux observations et revue de la littératureDrug-induced steatohepatitisThyroid Hormones and ThyromimeticsDesign of thyroid hormone receptor antagonists from first principlesRational Design and Synthesis of a Novel Thyroid Hormone Antagonist That Blocks Coactivator RecruitmentToxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondriaA designed antagonist of the thyroid hormone receptorSevere Intrahepatic Cholestasis Caused by Amiodarone Toxicity After Withdrawal of the DrugCardiac glycosides and drugs used in dysrhythmiasSide effects from amiodarone 15 November 1988Volume 109, Issue 10Page: 838-840KeywordsAdverse eventsCardiovascular therapyFatigueLiverNauseaSleepThyroxineToxicityVomiting ePublished: 1 December 2008 Issue Published: 15 November 1988 PDF downloadLoading ...